A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment
Table 1
Patient characteristics and serum 25(OH)D levels in the vitamin D-and placebo-treated active subgroup patients.
Characteristics
Vitamin D
Placebo
Number of patients
15
15
Gender (F/M)
9/6
9/6
Age (median, range)
37 (25–53)
32 (22–47)
BMI (median, range)
23.8 (19.7–31.2)
25.5 (19.3–32.3)
EDSS (median, range)
2 (0–3.5)
2 (0–4)
Disease duration (years, median, range)
3 (0.6–15.2)
1.5 (0.3–4.7)
ARR (mean, SD)
0.67 (0.38)
0.83 (0.37)
Duration of interferon therapy (months, median, range)
23 (4–82)
10 (2–53)
Vitamin D intake (μg, mean, SD)
2.04 (1.49)
2.71 (1.41)
Serum 25(OH)D at baseline (nmol/L, mean, range)
55 (35–82)
50 (24–81)
Serum 25(OH)D at 12 months (nmol/L, mean, range)
115 (78–163)
48 (30–68)
Calcium intake (mg, mean, SD)
1240 (357)
1357 (383)
BMI: body mass index; EDSS: Expanded Disability Status Scale; ARR: annual relapse rate.
